Key result
Isradipine and nifedipine retard both normalize blood pressure without altering metabolic control.
Why the study?
Does isradipine compared to nifedipine retard reduce blood pressure in hypertensive patients with type II diabetes mellitus?
RCT (n=20)
Does isradipine compared to nifedipine retard reduce blood pressure in hypertensive patients with type II diabetes mellitus?
Answers are grounded in this paper and cite their sources.
Isradipine and nifedipine retard effectively lower blood pressure in diabetic patients without modifying metabolic control.
Twenty patients were randomized to receive either 2.5 mg isradipine twice daily or 20 mg nifedipine retard once daily for 6 months. After 2 weeks of placebo wash-out, evaluations were carried out every 4 weeks. These evaluations included assessment of blood pressure, lipid profile, hemoglobin A1 sigma glucagon, C peptide, and insulin requirements. Both isradipine and nifedipine retard lowered systolic and diastolic blood pressures to normal values (P < .001). However, isradipine was accompanied by a decrease in heart rate (P < .005). Neither drug modified hemoglobin A1c or the glycemic profile. The endogenous insulin-secretion response decreased in both treatment groups (P < .05). In conclusion, isradipine and nifedipine retard are efficacious in the treatment of hypertension in patients with type II diabetes mellitus, and neither treatment produces modification of metabolic control.
No takes yet. Share an insight, caveat, or question.
Gomis et al. (1993) conducted an RCT in Hypertension with Type II Diabetes Mellitus (n=20). Isradipine vs. Nifedipine retard (20 mg once daily) was evaluated on Systolic and diastolic blood pressures (p=<0.001). Isradipine and nifedipine retard both lowered systolic and diastolic blood pressures to normal values (P<0.001) without modifying metabolic control.
Synapse has enriched 10 related papers. Consider them for comparative context: